Search | Clinical Trials Finder

Conditions: Atopic Dermatitis Eczema
Interventions: Investigational OTC Cream, 0.05% Desonide, Placebo Cream; Drug · Other
Lead sponsor: Procter and Gamble; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Raleigh, North Carolina • Chattanooga, Tennessee

Conditions: Restless Legs Syndrome
Interventions: Rotigotine, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 18
States / cities: Birmingham, Alabama • Jasper, Alabama • Gilbert, Arizona + 15 more

Conditions: Pain, Chronic, Pain, Joint, Pain Syndrome
Interventions: transdermal cream and or patch; Combination Product
Lead sponsor: Data Collection Analysis Business Management; Other
Eligibility: 18 Years to 64 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Land O' Lakes, Florida

Conditions: Coronary Artery Disease
Interventions: PROMUS Element Coronary Stent System, Aspirin, Thienopyridine; Device · Drug
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 21
States / cities: La Jolla, California • Sacramento, California • San Diego, California + 17 more

Conditions: Intracranial Hemorrhage Ruptured Aneurysm
Interventions: surgical management, Endovascular management; Procedure
Lead sponsor: Centre hospitalier de l'Université de Montréal (CHUM); Other
Eligibility: 18 Years and older
Enrollment: 1,724 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Diseases of Liver, Colon Carcinoma, Colorectal Carcinoma, Liver Metastases
Interventions: Computed Tomography Scan - 50% Dose Reduction, Computed Tomography Scan - 70% Dose Reduction, Deep Learning Image Reconstruction (DLIR); Diagnostic Test
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Triple Negative Breast Cancer
Interventions: Needle core biopsies, Needle core biopsies of metastatic lesion; Procedure
Lead sponsor: Jewish General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer
Interventions: [68Ga]Ga-NeoB, [177Lu]Lu-NeoB, Ribociclib, Fulvestrant, Goserelin; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 2
States / cities: Los Angeles, California • Houston, Texas

Conditions: Postoperative Pain, Obstetric Pain, Opioid Use
Interventions: Lidocaine patch, Placebo patch; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 52 Years · Female only
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diabetes
Interventions: Lidoderm; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 4
States / cities: Birmingham, Alabama • Hueytown, Alabama • Jacksonville, Florida + 1 more

Conditions: Head-and-neck Squamous Cell Carcinoma
Interventions: 89Zr-panitumumab IV, Panitumumab; Drug
Lead sponsor: Andrei Iagaru; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Postoperative Pain After Breast Reconstruction With Abdominal Flap
Interventions: Fentanyl, Inactive patch; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Peanut Allergy
Interventions: Viaskin Peanut 250 µg, Placebo; Biological
Lead sponsor: DBV Technologies; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 393 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 26
States / cities: Little Rock, Arkansas • Mission Viejo, California • Rolling Hills Estates, California + 21 more

Conditions: Allergic Contact Dermatitis
Interventions: Patch testing; Diagnostic Test
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years to 89 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Cigarette Smoker, Tobacco Use Disorder
Interventions: Behavioral Intervention, Laboratory Biomarker Analysis, Nicotine Patch, Questionnaire Administration, Smoking Cessation Intervention; Behavioral · Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Body Temperature Monitoring
Interventions: Moni-Patch Temperature Monitoring Patch System; Device
Lead sponsor: Murata Vios, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Restless Legs Syndrome, End-Stage Renal Disease
Interventions: Rotigotine, Placebo; Drug
Lead sponsor: UCB BIOSCIENCES GmbH; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Brandon, Florida • Newton, Massachusetts • West Seneca, New York + 3 more

Conditions: Pain
Interventions: lidocaine 70mg and tetracaine 70mg topical patch; Drug
Lead sponsor: ZARS Pharma Inc.; Industry
Eligibility: Up to 4 Months
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Multiple Sclerosis, Clinically Isolated Syndrome
Interventions: Not listed
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 10 Years to 45 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Solid Tumor, Hand-Foot Skin Reaction (HFSR)
Interventions: Topical Tazarotene, Placebo; Drug · Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Tobacco Use Cessation
Interventions: Counseling, Contingency management, Nicotine patches; Other · Behavioral · Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Tobacco Use Cessation
Interventions: Nicotine patch, Varenicline, Nicotine metabolism, Genetically-informed lung cancer risk score, NCI "Clearing the Air"; Drug · Genetic · Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Mammographic Density, Abnormal Mammogram
Interventions: CEE pill, Estradiol patch, Active Progesterone, Placebo tablet, Placebo patch, Placebo progesterone; Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 42 Years to 58 Years · Female only
Enrollment: 517 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Malignant Melanoma
Interventions: Atezolizumab, Cobimetinib, Vemurafenib; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 8
States / cities: Los Angeles, California • Aurora, Colorado • Sarasota, Florida + 3 more

Search by objective public record fields.

8-Week Atopic Dermatitis (AD) Treatment Study

Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)

Subjective Observational Study of Patients Using Transdermal Cream Medication And/Or Transdermal Patches With Or Without Oral Non-Narcotic Medications

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)

International Subarachnoid Aneurysm Trial II

Lesion Detection Assessment in the Liver: Standard vs Low Radiation Dose Using Varied Post-Processing Techniques

Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Lidocaine Patches After Cesarean Section

Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy

89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC

Postoperative Pain Control With Fentanyl Patch in Patients Undergoing Mastectomy and TRAM or DIEP Flap Reconstruction

Safety Study of Viaskin Peanut to Treat Peanut Allergy

Patient Experience and Quality of Patch Testing on the Legs vs Back

Behavioral Activation Therapy and Nicotine Replacement Therapy in Increasing Smoking Cessation

Moni-Patch Temperature Data Collection for Algorithm Development During Surgery

A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis

Pharmacokinetic Study of Synera™ in Neonates and Infants

AT RISK FOR MS - Clinical Conversion of Female Monozygotic Twins Discordant for CIS/MS

Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions

Low-Cost Contingency Management for Smoking Cessation

PRecision Interventions for SMoking in the SCCS

KEEPS Mammographic Density And Breast Health Ancillary Study

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma